BMN 349 + Placebo
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alpha 1-Antitrypsin Deficiency
Conditions
Alpha 1-Antitrypsin Deficiency
Trial Timeline
Feb 21, 2025 → Sep 1, 2025
NCT ID
NCT06738017About BMN 349 + Placebo
BMN 349 + Placebo is a phase 1 stage product being developed by BioMarin Pharmaceutical for Alpha 1-Antitrypsin Deficiency. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06738017. Target conditions include Alpha 1-Antitrypsin Deficiency.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06738017 | Phase 1 | Recruiting |
Competing Products
20 competing products in Alpha 1-Antitrypsin Deficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Drug-Carbamazepine (Tegretol XR) + Carbamazepine (Tegretol XR) Placebo | Novartis | Phase 2 | 52 |
| Belcesiran | Novo Nordisk | Phase 2 | 51 |
| belcesiran + Placebo | Novo Nordisk | Phase 1 | 32 |
| Belcesiran + Belcesiran + Belcesiran | Novo Nordisk | Phase 2 | 51 |
| VX-668 + Placebo | Vertex Pharmaceuticals | Phase 1 | 32 |
| VX-864 + Placebo | Vertex Pharmaceuticals | Phase 2 | 51 |
| VX-634 + Placebo | Vertex Pharmaceuticals | Phase 1 | 32 |
| VX-814 + Placebo | Vertex Pharmaceuticals | Phase 2 | 51 |
| VX-864 | Vertex Pharmaceuticals | Phase 2 | 51 |
| SAR447537 | Sanofi | Phase 2 | 51 |
| SAR447537 + Zemaira | Sanofi | Phase 2 | 51 |
| Alpha-1 Antitrypsin (human) | CSL | Phase 2 | 51 |
| CE1226 | CSL | Approved | 84 |
| Alpha1-proteinase inhibitor | CSL | Approved | 84 |
| ALN-AAT02 + Placebo + ALN-AAT02 | Alnylam Pharmaceuticals | Phase 1/2 | 38 |
| ARO-AAT Injection | Arrowhead Pharmaceuticals | Phase 1 | 30 |
| ARC-AAT Injection + Diphenhydramine | Arrowhead Pharmaceuticals | Phase 1 | 30 |
| ARC-AAT Injection | Arrowhead Pharmaceuticals | Phase 2 | 49 |
| Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor + Dose of 60 mg/kg alpha1-proteinase inhibitor | Baxter | Phase 1 | 30 |
| ARO-AAT | Arrowhead Pharmaceuticals | Phase 2 | 49 |